N/A
Completed N=130
Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological Disease (P07501)
Mycoses · leukemia
Source: ClinicalTrials.gov NCT01254318 ↗
Enrolled (actual)
130
Serious AEs
—
Results posted
Nov 2016
Primary outcomePrimary: Percentage of Participants With Non-Candida Invasive Fungal Infections at a Single Institution — 32.3 Percentage of participants
Summary
This will be a retrospective study that includes retrospective chart reviews at major institutions across Canada. The intent of the study is to generate both regional and national incidence data for non-Candida invasive fungal infections (IFI) in high risk participants. The study will include participants receiving stem cell transplant and high dose chemotherapy treatment for leukemia.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Non-Candida Invasive Fungal Infections at a Single Institution |
32.3 | — |
| SECONDARY Percentage of Participants With a Specific Fungal Pathogen at a Single Institution |
8.5; 1.5; 0.8; 21.5 | — |
| SECONDARY Percentage of Participants With Invasive Fungal Infections in Canada |
— | — |
Eligibility Criteria
Inclusion Criteria
- To be eligible for study inclusion, the participant must have:
- A hematological malignancy requiring high dose chemotherapy with or without bone marrow transplant
Exclusion Criteria
- The participant is not eligible for study inclusion if:
- Their IFI is not related to hematological malignancies.
Data sourced from ClinicalTrials.gov (NCT01254318). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.